The Clinical Conundrum in Managing Preterm Birth: Balancing Historical Trial Results, Society Guidelines, and Clinical Experience with a Contradictory Trial Outcome
The Clinical Conundrum in Managing Preterm Birth: Balancing Historical Trial Results, Society Guidelines, and Clinical Experience with a Contradictory Trial Outcome
Since its approval in 2011, 17-alpha hydroxyprogesterone caproate (17-OHPC, trade name Makena®, AMAG Pharmaceuticals, Inc, Waltham, MA) has been designated the “standard of care “ for treating pregnant patients with a history of spontaneous preterm birth (SPTB) by the American College of Obstetricians and Gynecologists (ACOG), the Society for Maternal Fetal Medicine (SMFM), and the American College of Nurse Midwives (ACNM). Several clinical trials and years of clinical experience have demonstrated its safety and efficacy.
This CME supplement details results of the PROLONG (Progestin’s Role in Optimizing Neonatal Gestation) trial evaluating 17-OHPC in patients with a history of a prior spontaneous singleton preterm delivery.
This activity is supported by an independent educational grant from AMAG Pharma…
Sponsor
This activity is supported by an independent educational grant from AMAG Pharma…
Since its approval in 2011, 17-alpha hydroxyprogesterone caproate (17-OHPC, trade name Makena®, AMAG Pharmaceuticals, Inc, Waltham, MA) has been designated the “standard of care “ for treating pregnant patients with a history of spontaneous preterm birth (SPTB) by the American College of Obstetricians and Gynecologists (ACOG), the Society for Maternal Fetal Medicine (SMFM), and the American College of Nurse Midwives (ACNM). Several clinical trials and years of clinical experience have demonstrated its safety and efficacy.
This CME supplement details results of the PROLONG (Progestin’s Role in Optimizing Neonatal Gestation) trial evaluating 17-OHPC in patients with a history of a prior spontaneous singleton preterm delivery.
To receive CME credit, please read the article and go to www.omniaeducation.com/ptb to access the posttest and evaluation.
Since its approval in 2011, 17-alpha hydroxyprogesterone caproate (17-OHPC, trade name Makena®, AMAG Pharmaceuticals, Inc, Waltham, MA) has been designated the “standard of care “ for treating pregnant patients with a history of spontaneous preterm birth (SPTB) by the American College of Obstetricians and Gynecologists (ACOG), the Society for Maternal Fetal Medicine (SMFM), and the American College of Nurse Midwives (ACNM). Several clinical trials and years of clinical experience have demonstrated its safety and efficacy.
This CME supplement details results of the PROLONG (Progestin’s Role in Optimizing Neonatal Gestation) trial evaluating 17-OHPC in patients with a history of a prior spontaneous singleton preterm delivery.
The Clinical Conundrum in Managing Preterm Birth: Balancing Historical Trial Results, Society Guidelines, and Clinical Experience with a Contradictory Trial Outcome
Display Headline
The Clinical Conundrum in Managing Preterm Birth: Balancing Historical Trial Results, Society Guidelines, and Clinical Experience with a Contradictory Trial Outcome